Document is current
Any future updates will be listed below
-
Authors
Chang, Ning
Moore, Hannah P.
Himeda, Charis L.
O’Brien, Terrence E.
Thomas, William
Roshanravan, Baback
Jones, Takako I.
Jones, Peter L.
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (2R01AR062587)
University of Nevada, Reno (Hitchcock Endowed Chair in Medical Biochemistry)
Renogenyx, Inc
- License Information
-
More Information
Article History
Received: 9 March 2026
Accepted: 9 June 2026
First Online: 16 June 2026
Declarations
Competing interests: CLH, TIJ, and PLJ are cofounders, shareholders, and members of the board of directors of Renogenyx, Inc., a company focused on bringing FSHD therapeutics to the clinic, and inventors on four international patent applications pertaining to the use of CRISPR inhibition for FSHD (WO/2024/020444, WO/2021/211325, WO/2025/019820) or muscle-specific regulatory cassettes for NMDs (WO/2024/020444).
